This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Clover Biopharmaceuticals Croissance future

Future contrôle des critères 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.

Informations clés

n/a

Taux de croissance des bénéfices

190.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	40.0%
Taux de croissance des recettes	47.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	27 Jul 2023

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

SZSC:2197 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).

Bénéfices vs marché: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market

Croissance élevée des bénéfices: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).

Croissance élevée des revenus: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Clover Biopharmaceuticals Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Founder recently bought HK$1.2m worth of stock

CEO & Executive Director recently bought HK$595k worth of stock

New major risk - Financial position

Clover Biopharmaceuticals, Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development

Clover Biopharmaceuticals, Ltd. announced that it has received $48.882447 million in funding

Clover Launches Covid-19 Booster Vaccine in the People’s Republic of China

Clover Biopharmaceuticals, Ltd. Provides Updates on COVID-19 Vaccine Commercial Launch

Founder recently bought HK$1.0m worth of stock

Clover Biopharmaceuticals, Ltd. Announces COVID-19 Vaccine, SCB-2019 (CpG 1018/ Alum), Has Been Evaluated by Relevant Authorities of the People's Republic of China and Included for Emergency Use in the PRC

Clover Biopharmaceuticals, Ltd. Announces Vaccine Candidate Reduced Household Transmission of SARS-COV-2 by 84% in Study Published in Clinical Infectious Diseases

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Founder recently bought HK$636k worth of stock

Founder recently bought HK$421k worth of stock

Founder recently bought HK$1.2m worth of stock

Clover Biopharmaceuticals, Ltd.'s COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Clover Biopharmaceuticals, Ltd. Announces Positive Data from Its Ongoing Phase 3 Study Evaluating IT’S SCB-2019

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd.’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

Clover Announces Positive Phase 2/3 Results in Adolescents for Its Covid-19 Vaccine

Clover Biopharmaceuticals, Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Clover Biopharmaceuticals, Ltd. Announces Executive Changes

Clover Biopharmaceuticals, Ltd. Announces New Positive Clinical Data in Individuals Vaccinated with A Third Dose of Scb-2019 as A Homologous Booster Against the Omicron Variant

Clover Biopharmaceuticals, Ltd. Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors

Clover Biopharmaceuticals, Ltd. Doses First Patient with Scb-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 1 Trial with SCB-2020S, Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate

Less than half of directors are independent

Clover Biopharmaceuticals, Ltd. Announces Board Changes

Clover Biopharmaceuticals, Ltd., Annual General Meeting, May 27, 2022

High number of new and inexperienced directors

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance